from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A humanized monoclonal antibody used in the prevention of respiratory syncytial virus infections.


Sorry, no etymologies found.


  • Motavizumab, however, was being designed to be more effective than Synagis, which is also known by its generic name palivizumab.

    Astra Limits Respiratory Drug's Development

  • While the American Academy of Pediatrics recommends use of the injectible drug, known generically as palivizumab, for certain preemies, UnitedHealth was denying coverage for a subgroup of infants.

    UnitedHealth Service Problems

  • Motavizumab is ~tenfold more potent than its predecessor, palivizumab

    Naturejobs - All Jobs

  • Overall, RSV hospitalization occurred in 44 (8. 3\%) of the 528 infants in whom palivizumab prophylaxis had been requested but denied compared with 42 (2. 9\%) of 1,429 infants in whom the drug had not been requested, respectively, p less than 0.01.

    Health News from Medical News Today

  • In 2003, the AAP released guidelines that recommend the use of palivizumab in high-risk infants 32 to 35 weeks GA who are younger than six months of age at the start of RSV season, provided they have at least two of the following risk factors: attendance in day care, school-age siblings, exposure to environmental pollutants (excluding tobacco smoke), congenital airway anomalies, and severe neuromuscular disease.

    Health News from Medical News Today

  • In 528 / 1967 (27\%) infants, palivizumab prophylaxis was requested by the treating physician but was not authorized.

    Health News from Medical News Today

  • Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection.

    Health News from Medical News Today

  • New data have emerged regarding three risk factors which may help pediatricians better identify which preterm infants are at high risk of severe respiratory syncytial virus (RSV) disease and may thus benefit from palivizumab (

    Health News from Medical News Today


Log in or sign up to get involved in the conversation. It's quick and easy.